AI & Technical question
For a model that turns patient-clinician conversations into structured clinical notes, what evaluation suite would you use beyond aggregate quality scores? Specify the failure modes you would prioritize, how you would segment risk by workflow or note type, and the thresholds or escalation paths you would require before declaring the model safe enough to scale.
- Abridge
- AI & Technical
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests designing a rigorous evaluation suite for a clinical documentation model beyond aggregate scores, prioritizing specific failure modes, segmenting risk, and defining scale-readiness thresholds.
How to approach it
- Go beyond aggregate quality score to specific failure modes: omission of clinically relevant information, fabrication of details not said in the conversation, and misattribution of who said what.
- Prioritize fabrication and omission of medication or diagnosis-relevant content as the highest-severity failure modes, since these have direct patient-safety implications.
- Segment risk by workflow, for example a routine follow-up versus a complex multi-problem visit, and by note type, since complexity correlates with higher error rates.
- Segment by specialty too, since terminology and note structure differ enough that an aggregate score can hide poor performance in one specialty.
- Set escalation paths: any fabrication involving medication, dosage, or diagnosis found in evaluation triggers a mandatory human review process before that pattern is considered safe.
- Require the model to clear a minimum performance bar on every high-risk segment individually, not just in aggregate, before declaring it safe enough to scale to that segment.
What a strong answer includes
- Names specific, safety-relevant failure modes, fabrication and omission of medication or diagnosis content, instead of a generic accuracy score.
- Segments risk by both workflow complexity and specialty, since aggregate scores can hide dangerous specialty-specific failures.
- Sets a per-segment minimum bar, not just an overall average, before scaling into any new specialty or note type.
- Defines a concrete escalation path for the most severe failure mode, medication or diagnosis fabrication, rather than treating all errors equally.
Common mistakes
- Relying on one aggregate quality score that can mask severe, safety-relevant failures in a subgroup.
- Treating omission and fabrication as equally low-severity issues when fabrication has more direct patient-safety risk.
- Declaring the model safe to scale broadly based on strong performance in only the specialties already tested.
Likely follow-up questions
- How would you handle a specialty where you don't have enough eval data yet?
- What would trigger you to pull the model from a specific note type after launch?
More ai & technical questions
- Abridge has a post-training approach that uses clinician edits, final notes, and EHR context to improve note generation. How would you define the hypotheses, stage gates, and success metrics to take it from offline research to shadow mode to a limited production launch? What evidence would be required at each step to continue, pause, or kill the effort?Abridge · AI & Technical · Hard
- Abridge has access to de-identified conversations, clinician edits, final signed notes, EHR context, and downstream care actions, but each signal differs in coverage, cost, bias, and clinical relevance. How would you prioritize which signals to use first for post-training, and what framework would you use to decide whether a sparse, subjective, or expensive signal is still worth operationalizing?Abridge · AI & Technical · Hard
- A chart-aware CDS assistant must feel fast enough for live clinical use while staying reliable and evidence-grounded. How would you work with engineering and ML to define the system tradeoffs and product requirements around latency, retrieval quality, grounding, fallback behavior, and failure handling, and what technical or model-level changes would you prioritize first if response time improved only by reducing answer quality?Abridge · AI & Technical · Hard
- Abridge has a new AI-assisted clinician workflow whose model quality is improving but still imperfect. What launch criteria would you set before exposing it in live care, how would you combine offline evals, human review, and UX guardrails, and how would you phase the rollout to manage clinical and compliance risk?Abridge · AI & Technical · Hard
- Production monitoring shows a model improves average note quality but increases rare critical errors. How would you investigate whether this is a measurement artifact, a distribution shift, or a real safety regression, and how would you decide between shipping, pausing, rolling back, or narrowing scope?Abridge · AI & Technical · Hard
- Abridge explicitly uses LLM judges, rule-based evaluators, human annotation, and online monitoring. How would you decide which of these methods belongs at each stage of the eval lifecycle, and what failure modes, cost/speed tradeoffs, and confidence limits would you communicate before teams rely on them for launch decisions?Abridge · AI & Technical · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 1: Foundations: the model and the decisions it forces on you
- Chapter 8: Evals: define good and make the number defensible
- Chapter 6: Agents and agentic architecture